Images List Premium Download Classic

Autoimmune Disorder

Autoimmune Disorder-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors
Active Biotech Ab
June 07, 2018 - N°20180155330

A compound of formula (i), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between si 00a9 and interaction partners such as rage, tlr4 and emmprin and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders..
Arsenic trioxide for treatment of pin1-associated disorders
Beth Israel Deaconess Medical Center, Inc.
June 07, 2018 - N°20180153934

The present invention relates to the treatment of pin1-associated disorders (e.g., disorders characterized by elevated pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of pin1 activity..
Tricyclic fused thiophene derivatives as jak inhibitors
Incyte Holdings Corporation
May 31, 2018 - N°20180148460

The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase (jak) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Lgr5+ somatic stem cells
Stembios Technologies, Inc.
May 17, 2018 - N°20180135009

A method for treating a condition, comprising administering to a subject in need thereof a composition that contains somatic stem cells that are 2 to less than 6 micrometers in size and lgr5+, wherein the condition is selected from the group consisting of neurodegenerative disorder, muscle-degenerative disease, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart disorder, circulatory disorder, a condition associated with ...
Antigen-binding proteins that antagonize leptin receptor
Regeneron Pharmaceuticals, Inc.
May 10, 2018 - N°20180127508

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and antagonize lepr signaling.
Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental ...
Mitochon Pharmaceuticals, Inc.
May 10, 2018 - N°20180125794

A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gb s), metabolic syndrome, muscular dystrophy or duchenne ...
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel aryl-cyanoguanidine compounds
Bayer Pharma Aktiengesellschaft
May 03, 2018 - N°20180118722

The present invention relates to protein-lysine n-methyltransferase smyd2 (set and mynd domain-containing protein 2) inhibitors, in particular smyd2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (i), wherein r1, r3, r4, r5 and n have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative ...
Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity
The Methodist Hospital
May 03, 2018 - N°20180117176

Porous silicon (psi) microparticles (psm) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent psm-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies.
Shmt inhibitors
The Trustees Of Princeton University
May 03, 2018 - N°20180117010

The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (shmt) inhibitor, and in particular the administration of pyrazolopyran compounds of formula (vi) as presently described, wherein the compounds are capable of inhibiting a mammalian shmt, such as human shmt1 and/or shmt2. The treatment method further ...
Autoimmune disorder treatment using rxr agonists
Trustees Of Dartmouth College
May 03, 2018 - N°20180116985

The present specification provides rxr agonist compounds, compositions comprising such rxr agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such rxr agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation ...
Boronic acid derivatives
Merck Patent Gmbh
April 19, 2018 - N°20180105539

Compounds of formula (i) are inhibitors of lmp7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.. .
Boronic acid derivatives
Merck Patent Gmbh
April 19, 2018 - N°20180105538

Compounds of formula (i) are inhibitors of lmp7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.. .
Method of treating skin disorders
Mymd Pharmaceuticals, Inc.
April 19, 2018 - N°20180104229

In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism.
Autoimmune Disorder Patent Pack
Download + patent application PDFs
Autoimmune Disorder Patent Applications
Download + Autoimmune Disorder-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Autoimmune Disorder-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Controlled release pharmaceutical compositions comprising a fumaric acid ester
Fwp Ip Aps
April 12, 2018 - N°20180098957

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
Targeted apheresis using binding agents or ligands immobilized on membranes
April 05, 2018 - N°20180093032

This invention teaches a method of targeted apheresis that can be used to treat a variety of different diseases including infectious diseases, autoimmune disorders, and reducing circulating biomarkers associated with certain disorders e.g. Pre-eclampsia.
Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
Fwp Ip Aps
April 05, 2018 - N°20180092875

The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf), more specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix ...
Substituted n-(lh-indazol-4-yl)imidazo[l,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine ...
March 29, 2018 - N°20180086758

And pharmaceutically acceptable salts thereof in which r1, r2, r3, r4, r5 and r6 have the meanings given in the specification, are inhibitors of cfms and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.. .
Eluting matrix and uses thereof
The General Hospital Corporation
March 15, 2018 - N°20180075706

Cxcl12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.. .
Shmt inhibitors
The Trustees Of Princeton University
March 15, 2018 - N°20180072751

The disclosure provides compounds of formulae (i)-(ix). The disclosed compounds are capable of inhibiting a mammalian shmt.
Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody
Dnx Biotech, Llc
March 08, 2018 - N°20180066049

Tumor necrosis factor-α (tnfα) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of tnf production is implicated in a variety of human diseases including alzheimer's disease, cancer, major depression, and inflammatory bowel disease.
Display platform from bacterial spore coat proteins
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
March 01, 2018 - N°20180055925

A particle construct is disclosed that includes a synthetic core with a solid surface coated with a lipid bilayer, spovm adhered to the lipid bilayer; and spoiva adsorbed to the spovm. In additional embodiments, an agent of interest can be covalently linked to the spoiva.
Loading